Analysis: U.S. midterms dampen Big Pharma hopes for drug price policy change
Written by Black Hot Fire Network on November 18, 2022
WASHINGTON, Nov 18 (Reuters) - The divided U.S. Congress after the November midterm elections undermines pharmaceutical companies who want to weaken a new law that allows the government to negotiate drug prices, Republican strategists, policy experts and pharmaceutical executives say.
Democratic President Joe Biden's signature Inflation Reduction Act, which Democrats passed in August against 
